Technical Analysis for VSTM - Verastem, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Support | Bullish | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Crossed Above 20 DMA | Bullish | 1.78% | |
Outside Day | Range Expansion | 1.78% | |
Wide Bands | Range Expansion | 1.78% | |
Fell Below 20 DMA | Bearish | 5.54% | |
1,2,3 Pullback Bullish | Bullish Swing Setup | 5.54% | |
Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 5.54% | |
NR7 | Range Contraction | 5.54% | |
Inside Day | Range Contraction | 5.54% |
Alert | Time |
---|---|
Up 5% | 1 day ago |
Possible Inside Day | 1 day ago |
Rose Above 10 DMA | 1 day ago |
10 DMA Resistance | 1 day ago |
Up 3% | 1 day ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/06/2024
Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing proprietary small molecule drugs targeting cancer stem cells (CSCs) with companion diagnostics. Its programs target the Focal Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. The company's lead FAK inhibitor, VS-6063, is in Phase I/Ib testing in ovarian cancer, as well as developing for the treatment of mesothelioma and breast cancer. It is also developing FAK inhibitor VS-4718 and PI3K/mTOR inhibitor VS-5584 in patients with advanced cancers. The company's product candidates target CSCs that have been implicated in aggressive cancers, metastasis, and chemotherapeutic resistance. Verastem, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Oncology Stem Cell Breast Cancer Ovarian Cancer Treatment Of Breast Cancer Signal Transduction Cancer Research mTOR Companion Diagnostic Metastasis Advanced Cancer Mesothelioma Advanced Cancers Cancer Stem Cell Cancer Stem Cells Mtor Inhibitors
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Oncology Stem Cell Breast Cancer Ovarian Cancer Treatment Of Breast Cancer Signal Transduction Cancer Research mTOR Companion Diagnostic Metastasis Advanced Cancer Mesothelioma Advanced Cancers Cancer Stem Cell Cancer Stem Cells Mtor Inhibitors
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 14.22 |
52 Week Low | 2.1 |
Average Volume | 929,488 |
200-Day Moving Average | 6.18 |
50-Day Moving Average | 3.32 |
20-Day Moving Average | 3.90 |
10-Day Moving Average | 4.06 |
Average True Range | 0.33 |
RSI (14) | 56.33 |
ADX | 34.89 |
+DI | 24.92 |
-DI | 13.23 |
Chandelier Exit (Long, 3 ATRs) | 3.80 |
Chandelier Exit (Short, 3 ATRs) | 4.10 |
Upper Bollinger Bands | 4.39 |
Lower Bollinger Band | 3.41 |
Percent B (%b) | 0.6 |
BandWidth | 25.24 |
MACD Line | 0.19 |
MACD Signal Line | 0.23 |
MACD Histogram | -0.0449 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 4.51 | ||||
Resistance 3 (R3) | 4.50 | 4.32 | 4.43 | ||
Resistance 2 (R2) | 4.32 | 4.19 | 4.33 | 4.40 | |
Resistance 1 (R1) | 4.16 | 4.11 | 4.24 | 4.17 | 4.37 |
Pivot Point | 3.98 | 3.98 | 4.02 | 3.99 | 3.98 |
Support 1 (S1) | 3.82 | 3.85 | 3.90 | 3.83 | 3.63 |
Support 2 (S2) | 3.64 | 3.77 | 3.65 | 3.60 | |
Support 3 (S3) | 3.48 | 3.64 | 3.58 | ||
Support 4 (S4) | 3.49 |